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Ab s t r Ac t
Lymphangiomyomatosisis a rare disease characterized by a proliferation of abnormal smooth muscle cells responsible for infiltration with the 
destruction of tissue architecture and genesis of cystic lung and lymphatic lesions. In addition to lung damage, Bourneville’s tuberous sclerosis 
(BTS) also affects the skin, brain, retina, kidneys, and, less frequently, the heart and bone. 
We report the case of a young patient with bilateral pneumothorax revealing pulmonary lymphangiomyomatosis in the context of 
Bourneville’stuberoussclerosis BTS. 
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In t r o d u c t I o n
There is a genetic relationship with  Bourneville’s tuberous 
sclerosis (BTS) and lymph angiomyomatosis, including the 
participation of the tuberous sclerosis complex 2 (TSC2) gene, 
that’s why clinicians need to be conscious of the association 
and to make STB assessment in the face of any suspicion of 
lymph angiomyomatosis (namely bilateral pneumothorax) 
Observation 
She is a patient aged 25 yo, mentally-retarded, followed for 
an undocumented kidney problem for the last 4 years. 
Since 4 months, she reports dyspnea of effort with 
aggravation of the bilateral-lumbar pain. 
The symptomatology increased one-month ago by 
a dyspnea of rest with a dry cough without chest pain or 
hemoptysis, which prompted her to go to the emergency, 
the clinical examination found a polygenic patient at 32 
c/min SaO2 at 79%, intercostal draught with a bilateral air 
epileptic syndrome. 
A chest X-ray was taken, showing a bilateral pneumothorax 
of great abundance on the right and a partial pneumothorax 
on the left. 
The patient was drained on both sides with good 
evolution. 
Elsewhere, skin examination found fibrous plaques on the 
forehead, papular lesions on both cheeks and on the wings of 
the nose, acromic plaques on the external surface of the left 
thigh, 2-hypochromic macules on the left thigh, and a small 
number of fibrous plaques on the right thigh. 
The abdominal examination found bilateral lumbar 
tenderness and neurological examination is without 
peculiarities 
cranial and thoracoabdominal scan (done after an 
accidental fall of the left drain) objectified a bilateral cystic 
pulmonary lesion and a right pneumothorax (Figure 1). 
in addition to the chest abnormalities, the scan showed 
subependymal cerebral nodules (Figure 2) and renal mass 
on both sides (angiomyolipoma) (Figure 3). 
The diagnosis of Bourneville’s tubular sclerosis was retained. 
in search of other abnormalities, a cardiology consult with 
cardiac echography ruled out a heart condition as well as an 
ophthalmological examination. 
Surgical pleurodesis was proposed, but the patient was 
recused by the anesthetist because of the major risk of 
ventilating pathological lungs. 
Figure 1: CT scan showing bilateral cystic pulmonary lesion and a 
right pneumothorax in the context of tuberous bourneville sclerosis.
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The evolution was marked by the return of the lung to the 
wall, mTOR inhibitors were prescribed to the patient rather 
discharge from hospital. 
dI s c u s s I o n
Lymphangiomymatosisis a rare disease in young women, 
in a period of genital activity, the average age of diagnosis 
varies between 30 and 45 years.[1] 
During the Bourneville’s tubular sclerosis, the physio-
pathology implies the mutation of the tumor suppressor 
genes TSC1 and TSC2. 
Pulmonary lymph angiomyomatosis is often discovered 
in the course of a pneumothorax. The Suspicion of tuberous 
bourneville sclerosis requires a complete systematic review 
in search of other systemic disorders, the diagnosis of BTS 
is based on clinical, radiological, and some times genetic 
criteria (Table 1).[2] 
It is the identification of the two genes responsible for 
the disease, which, by making it possible to understand how 
these tumors were forming, paved the way for treatment 
medical. A crucial discovery was that protein seconded 
by these two genes form a complex that physiologically 
inhibits the mammalian target of rapamycin (mTOR) signaling 
pathway (for mammalian Target Of Rapamycin), which has 
a role central to the physiological control of proliferation 
cell phone. It appeared that when one of these proteins is 
Table 1: Diagnostic criteria  of Bourneville’stubularsclerosis (Northrup et al.)
Genetic diagnostic criteria Clinical diagnostic criteria
identification of a pathogenic mutation in the TSC1 or TSC2 gene 
in DNA extract edfrom normal tissues is sufficient to make a definit 
ediagnosis of Bourneville’stubularsclerosis
In 10 to 25% of people withBourneville’stubularsclerosis, 
conventional genetic tests do not reveal a mutation. However, a 
normal result does not rule out the diagnosis.
Major criteria :
1- Hypomelanic spots (>3), minimum 5mm in diameter
2- Angiofibromas (>3) or cephalic fibrous plaques.
3- Nailfibroids
4- Grief Skin Plates
5- Multiple retinal hamartomes
6- Cortical dysplasia (cortical tubers or lines of radial migration in the 
white matter)






1- “Confetti” skin lesions
2- Wells in dental enamel (>3)
3- Intra-oral fibroids (>2)
4- Achromicretinal spots
5- Multiple renal cysts
6- Non-renal Hamartomes
Definite diagnosis: 2 major criteria or 1 major and 2 minor criteria
Possible diagnosis: 1 major criteria  or more than 2 minor criteria
A combination of the two major clinical criteria, which are Lymphangioleiomyomatosis and Angiomyolipomas, without other features of 
tuberous bourneville sclerosis, is not considered for definitive diagnosis.
Figure 2: Cranial scan showing a subependymal cerebral nodule in 
the context of tuberous bourneville sclerosis.
Figure 3: Abdominal scan showing renal angiomyolipoma in the 
context of tuberous bourneville sclerosis.
Pulmonarylymphangiomyomatosis in Bourneville’s tuberoussclerosis: Case Report
International Journal of Health and Biological Sciences, Apr-Jun, 2020; 3(2):6-88
deficient due to a mutation of TSC1 or TSC2, the excessive 
activation of this signaling channel mTOR conducts, in tissues 
where a second somatic mutation, to the tumor proliferation 
that goes constitute the hamartoma. Hence the use of mTOR 
inhibitors (already used in organ transplantation): sirolimus 
or rapamycin (Rapamune®) or everolimus (Certican®). 
The effect of these drugs was first tested in animal 
models and then in a few patients with large cerebral or 
renal hamartoma. The result is favorable; clinical trials 
were conducted in patients with renal manifestations,[3] 
pulmonary,[3] and cerebral.[4] Results are impressive and 
consistent: after 6 months of treatment, the size of the tumors 
in this various organs is reduced by more than 30% in 75% of 
cases. of patients.[5] In two recent clinical trials reported using 
ever olimusin 117 patients treated for cerebral astrocytoma 
(84% under the age of 18 years of age) and 118 treated for renal 
MLA, a reduction of size of more than 50% of the targeted 
tumour is obtained, at the After one year, in 35 and 42% of 
patients, respectively.[6,7] At the end of the current follow-up 
(19-33 months; mean 28 months), the lesions continue to 
decrease or in any case stabilize. However, thesedrugs do 
cause enough often some side effects, including the main 
are stomatitis and respiratory tract infections.[8,9] 
Rapamycin has also been tested in topical use. at 
concentrations ranging from 0.003 to 1% for the treatment 
of angiofibroma of the face, with results very encouraging 
both in size and appearance. 
co n c lu s I o n 
Pulmonary lymphangiomymatosis most often progresses 
to chronic respiratory failure within a few years or decades. 
Hormonal therapy has not been shown to be effective in the 
absence of controlled clinical trials. Lung transplantation is 
the last therapeutic resort; rare recurrences of transplant 
edlungs have been reported.
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